Volumen: 17 # Number : 3
Publication Date : Septiembre - Diciembre Year: 2013
Multiple Myeloma and Renal Impairment
Authors: Manciola F, Stemberg E
Abstract: Renal impairment (RI) is a common and severe complication of patients with Multiple Myeloma (MM) and is associated with poorer outcomes. RI is generally caused by the accumulation and precipitation of light chains, which form casts in the distal tubules, resulting in renal obstruction. In addition, myeloma light chains are also directly toxic on proximal renal tubules, contributing to renal dysfunction. An early improvement in renal function is associated with a longer survival; therefore, rapid intervention to reverse renal dysfunction is critical for the management of these patients, particularly for those with light chain cast nephropathy. Available data support the safety and efficacy of Bortezomib-based therapies in this setting and thus Bortezomib plus Dexamethasone is the recommended treatment for patients with MM and RI of any grade.
Key words: Multiple Myeloma / Renal Impairment
Treatment
Pages : 256-265
|
